Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pluronic Lecithin
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Medisca
Deal Size : Undisclosed
Deal Type : Acquisition
Medisca Acquires all IP assets of Maxima Pharmaceuticals Including the DIFFUSIMAX® Brand
Details : Acquisition includes, DIFFUSIMAX® and DIFFUSIMAX®10 liposomal bases (pluronic lecithin organogel or PLO gel), products used for preparing compounded topical formulations, as well as all intellectual property assets of Maxima Pharmaceuticals.
Product Name : Diffusimax
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 28, 2022
Lead Product(s) : Pluronic Lecithin
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Medisca
Deal Size : Undisclosed
Deal Type : Acquisition
Reset All
